What does QurieGen do?
QurieGen is a cellular technology company based in Nijmegen, the Netherlands. The company develops QuRIE-seq, a patented platform that enhances the drug discovery and development process by simultaneously quantifying mRNA, membrane proteins, intracellular proteins, and phosphoproteins.
How much did they raise?
The company raised €2.2M in a funding round supported by investors such as Tensor Ventures, Lighthouse Ventures, BSV Ventures, Moondust Ventures, 22 Hor Invest, and Tim Draper from Draper Associates. Although the round is categorized as series_unknown, the capital raise marks a significant step in bolstering their research and development efforts.
What are their plans for the money?
The funds will be used to expand QurieGen’s operations and further invest in research and development. This investment is expected to amplify the capabilities of the QuRIE-seq platform, potentially accelerating advances in drug discovery and the overall impact on healthcare innovation.
What have they achieved so far?
QurieGen has already established a strong foundation by leveraging a robust scientific base in the Netherlands and a vibrant technology ecosystem in Poland, positioning the company at the forefront of cellular technology innovation.
